Core Viewpoint - The innovative pharmaceutical stocks have shown a rebound, with notable increases in share prices for several companies, driven by recent policy developments and market dynamics [1] Group 1: Stock Performance - Gilead Sciences-B (01672) increased by 10.26%, reaching HKD 13.11 [1] - Kangfang Biotech (09926) rose by 4.15%, reaching HKD 123.1 [1] - Zai Lab (09688) saw a 3.36% increase, reaching HKD 15.69 [1] - Xiansheng Pharmaceutical (02096) grew by 2.9%, reaching HKD 13.48 [1] Group 2: Policy Developments - In November, the National Healthcare Security Administration initiated negotiations for the 2025 National Basic Medical Insurance Drug List and the pricing consultation for the commercial insurance innovative drug list [1] - The fourth batch of traditional Chinese medicine centralized procurement was launched, and new policies regarding medical devices were introduced in Beijing [1] - The State Council meeting outlined plans to promote provincial-level coordination of basic medical insurance [1] Group 3: Market Insights - Bohai Securities highlighted the importance of the upcoming release of the new basic medical insurance drug list and the first commercial insurance innovative drug list in early December, indicating potential investment opportunities in related pharmaceutical companies [1] - Zhongyou Securities noted that despite a temporary vacuum in domestic BD outbound transactions, several collaborations with multinational corporations (MNCs) have emerged since Q4, reflecting the recognition of domestic innovative drug companies' R&D capabilities [1] - The strong competitive advantages of China's innovative drug industry, including the capacity of the industry chain, pipeline quantity and quality, and R&D efficiency, are expected to drive long-term industry trends [1]

Core Viewpoint - The Hong Kong innovative drug concept stocks have shown a rebound today, indicating a positive market sentiment towards this sector [1] Company Performance - Gilead Sciences-B (01672.HK) increased by 10.26%, reaching HKD 13.11 [1] - CanSino Biologics (09926.HK) rose by 4.15%, trading at HKD 123.1 [1] - Zai Lab (09688.HK) saw a gain of 3.36%, with a price of HKD 15.69 [1] - Ascletis Pharma (02096.HK) grew by 2.9%, priced at HKD 13.48 [1]

Core Viewpoint - The innovative drug sector is experiencing a rebound, with notable stock price increases for several companies following recent policy developments in China's healthcare system [1] Group 1: Stock Performance - Gilead Sciences-B (01672) increased by 10.26%, reaching HKD 13.11 [1] - Kangfang Biotech (09926) rose by 4.15%, priced at HKD 123.1 [1] - Zai Lab (09688) saw a 3.36% increase, trading at HKD 15.69 [1] - Xiansheng Pharmaceutical (02096) grew by 2.9%, now at HKD 13.48 [1] Group 2: Policy Developments - In November, the National Healthcare Security Administration initiated negotiations for the 2025 National Basic Medical Insurance Drug List and the pricing of innovative drugs for commercial insurance [1] - The fourth batch of traditional Chinese medicine procurement has commenced, and new policies regarding medical devices have been introduced in Beijing [1] - The State Council has outlined plans to advance provincial-level coordination of basic medical insurance [1] Group 3: Investment Opportunities - Bohai Securities highlighted the importance of the upcoming release of the new basic medical insurance drug list and the first commercial insurance innovative drug list in early December, suggesting potential investment opportunities in related pharmaceutical companies [1] - Zhongyou Securities noted that despite a temporary lull in domestic BD (business development) transactions, there have been multiple collaborations with multinational corporations (MNCs) since Q4, indicating ongoing interest in domestic innovative drug companies [1] - The purchasing behavior of overseas MNCs is seen as a validation of the innovative research capabilities of domestic companies, reflecting China's strong competitive advantages in the global innovative drug industry [1]

Group 1: Market Performance - The Hong Kong Innovation Drug ETF (159570) rebounded by 1.5% after four consecutive declines, with trading volume exceeding 1.2 billion [1] - The ETF has seen a net inflow of over 180 million in the past five days, with a total size exceeding 23.2 billion as of December 3 [1] - Major stocks within the ETF, such as Kangfang Biotech and Kintor Pharmaceutical, experienced gains of over 3% [3] Group 2: Regulatory Developments - On December 3, Xinlitai received approval from the drug regulatory authority to conduct clinical trials for its innovative small molecule drug SAL0140 for chronic kidney disease [3] Group 3: Policy Environment - A significant policy shift is expected in 2025, with the introduction of a commercial insurance innovation drug directory aimed at expanding coverage beyond basic medical insurance [5] - The overall policy direction encourages innovation and aims to alleviate payment pressures, which is expected to positively impact industry sentiment and fundamentals [5] Group 4: Financial Outlook - Leading innovative drug companies are projected to achieve breakeven within the next two years, enhancing market confidence in their profitability [8] - The financial performance of the covered biotech companies indicates a sustained recovery in the pharmaceutical sector [8] Group 5: Investment Trends - The overseas investment environment for innovative drugs remains strong, with record-high transaction numbers and amounts in 2025 [11] - By the end of Q3 2025, 103 outbound transactions were completed, totaling over 92 billion, surpassing the total for 2024 by 77% [11] Group 6: Capital Flow - Both domestic and foreign investments in the Hong Kong pharmaceutical sector have increased, with domestic holdings at 22.1% and foreign holdings at 38.1% as of November 10 [12] - The pharmaceutical sector is expected to attract more capital due to its valuation being below historical averages [12]

Group 1 - The Hong Kong innovative drug sector showed strength in early trading, with companies like Kangfang Biopharma and Zai Lab rising over 3% [1] - The Hang Seng Innovative Drug ETF (159316) saw its index increase by over 1%, reflecting positive market sentiment [1] - Chinese innovative drug development is becoming a significant global player, with increasing overseas licensing transactions driving growth in the sector [1] Group 2 - The pharmaceutical industry is entering a critical phase characterized by "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - Companies are actively exploring diverse overseas expansion paths, indicating a strategic shift towards international markets [1] - By 2026, opportunities in innovative commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions are expected to emerge [1] Group 3 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is one of the first "pure" 100% innovative drug indices, accurately reflecting the overall performance of China's innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index, providing investors with a convenient way to seize industry development opportunities [1]

Group 1 - The Hang Seng Healthcare Index (HSHCI) has risen by 1.17% as of December 4, 2025, with notable increases in stocks such as InnoCare Pharma (up 4.91%), CanSino Biologics (up 4.65%), and MicroPort Scientific (up 4.51%) [1] - The 11th batch of national centralized procurement results was released on November 7, including 453 products across 55 varieties, with an average price reduction of approximately 75% compared to the highest valid bid [1] - The upcoming ESMO Asia 2025 conference will take place from December 5-7, and the 67th American Society of Hematology (ASH) meeting will be held from December 6-9, which are expected to catalyze data releases in the healthcare sector [1] Group 2 - The top ten weighted stocks in the Hang Seng Healthcare Index (HSHCI) account for 60.48% of the index, including companies like BeiGene, Innovent Biologics, and WuXi Biologics [2] - The Hang Seng Healthcare ETF (159557) closely tracks the HSHCI, providing a market reference for the performance of healthcare securities listed in Hong Kong [2] - Investors without stock accounts can access the Hong Kong healthcare sector investment opportunities through the Hang Seng Healthcare ETF linked fund (018433) [2]

Group 1 - The core viewpoint is that the innovative drug sector is expected to remain the most important investment theme in the pharmaceutical sector for the upcoming year, with significant positive catalysts emerging [2] - The Hong Kong pharmaceutical ETF (159718.SZ) has seen a 0.74% increase, with notable gains in constituent stocks such as Kangfang Biopharma (4.57%), MicroPort Scientific (4.15%), and Zai Lab (3.95%) [1] - The U.S. job market showed a significant decline in November, with private sector jobs decreasing by 32,000, the largest drop in two and a half years, which has heightened expectations for a Federal Reserve interest rate cut [1] Group 2 - The pharmaceutical sector has experienced a 2-3 month adjustment period, leading to a relative low in stock prices, market expectations, and institutional allocations, thus enhancing investment safety margins [2] - Multiple favorable policies are set to be released, including December's medical insurance negotiations and international conferences, which are expected to positively impact the industry [2] - The U.S. biotechnology index (XBI) has risen by 2.84%, reflecting a strong performance in the healthcare sector, with expectations of a gradual recovery in global innovative drug financing and demand [1][2]

相比恒生科技指数，国证港股通科技指数减配消费零售，超配医药生物、硬件设备，科技成色更足。 2017年以来，国证港股通科技指数年化收益超12%，长期跑赢恒生科技指数、中证港股通科技指数等同 类港股科技指数。 消息面上，美国11月"小非农"创两年半来最大降幅，美联储降息预期进一步升温。参照历史数据，在美 联储降息周期内，港股科技成长资产反弹空间普遍大于A股。招商香港报告中指出，港股边际利好正在 积聚，已迎来上行转折点，AI等科技领域的发展前景受到关注。 港股通科技ETF（159101.SZ）跟踪港股通科技指数，成分股均为港股通标的，相比恒生系列ETF，港股 通类ETF不占QDII额度，流动性更优，更容易获得资金积极抢筹。 12月4日，A股港股市场开盘一度惯性下探，但临近午盘强势翻红，港股弹性更大，截至发稿，恒生科 技指数涨0.80%，港股通科技指数涨幅更为领先，盘中涨超1.3%。 港股通科技指数成分股方面，优必选、地平线机器人、康方生物、华虹盘中涨超4%，金山云、小米集 团、信达生物、哔哩哔哩涨超2%，中兴通讯、美团等也止跌反弹。 ...

Group 1 - The Hong Kong stock market opened slightly higher on December 4, with the Hang Seng Index rising by 0.17% and the Hang Seng Biotechnology Index increasing by over 1% [1] - The Hong Kong Stock Connect Technology ETF (513860) saw a gain of 1.22%, with significant increases in constituent stocks such as Kingsoft Biotechnology and CanSino Biologics, both rising nearly 4% [1] - As of December 3, the Hong Kong Stock Connect Technology ETF (513860) attracted a total of 410 million yuan over the past nine trading days, with a net inflow of 74.36 million yuan on December 2 [1] Group 2 - Guosen Securities emphasizes that AI will remain a key focus through 2026, driven by the need for accelerated domestic hardware production and the expectation of more AI applications being implemented [2] - The Hong Kong Stock Connect Technology ETF (513860) closely tracks the CSI Hong Kong Stock Connect Technology Index, which selects 50 large-cap, high R&D investment, and fast-growing technology companies [2] - The top ten weighted stocks in the index include major players such as Alibaba-W, Tencent Holdings, SMIC, BYD, and Xiaomi Group-W [2]

展望后市，12月医保谈判、商保目录及国际会议等多重利好集中释放；BD交易持续活跃，今年已出现 多笔超10亿美元授权。创新药产业趋势不变，随着行业正向催化的陆续落地，板块情绪也有望逐步恢 复。当前板块已提前调整至半年线，估值具备吸引力，建议关注港股医药ETF(159718)。 12月4日早盘，港股高开，隔夜美股标普生物科技大涨2.84%，港股医药ETF(159718.SZ)高开0.74%。成 分股金斯瑞生物科技(01548)上涨4.15%，康方生物(09926)上涨2.96%，同源康医药-B(02410)上涨 2.82%，再鼎医药(09688)，微创机器人-B(02252)等个股跟涨。 消息面上，美国11月"小非农"创两年半来最大降幅，美联储降息预期进一步升温。最新公布的ADP就业 数据显示，11月私营企业减少3.2万个工作岗位，为2023年3月以来最大降幅，远不及市场预期的增加1 万个。据CME"美联储观察"，美联储12月降息25个基点的概率接近90%。 隔夜美股标普生物科技指数（XBI）大涨2.84%，美股医疗保健年初至今涨幅第一，XBI持续走强创近3 年新高，而海外尤其是美国生物医药投融资金额25Q3呈现 ...